Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared a post on X:
“How should HCC clinical trials be designed to ensure meaningful and globally comparable outcomes?
A multisociety Delphi consensus produced 102 statements harmonizing target populations, end points, stratification, and clinical benefit benchmarks across all HCC stages.
Consensus statement by Josep M. Llovet et al. has recently been published in Nature Reviews Clinical Oncology.
Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement.”
Title: Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement
Authors: Josep M. Llovet, Ezequiel Mauro, Lorenza Rimassa, Vincenzo Mazzaferro, Matthias Pinter, Robin Kate Kelley, Stephen L. Chan, Laura Kulik, Anjana Pillai, Lewis Roberts, Bruno Sangro, Teresa Casanovas, David E. Kaplan, Arndt Vogel, Mark Yarchoan, Richard S. Finn, Tim Meyer, Amit G. Singal
Read the article here.
Other articles featuring Hong Jae Chon on OncoDaily.
